February 22nd, 2019

A full text version of this article is available.
To access article obtain online access here or login
Comparison of the Efficacy of Cabergoline and Bromocriptine in a Rat Model of Ovarian Hyperstimulation Syndrome
Authors:  Pinar Gulsen Coban, M.D., Ayla Sargin Oruc, M.D., M. Gulnur Ozaksit, M.D., Aysegul Demirtas, M.Sc., Fatma Helvacioglu, Ph.D., Pinar Ayran Fidan, M.D., Levent Sirvan, M.D., and Semra Eroglu, M.D.
  OBJECTIVE: To compare cabergoline and bromocriptine for their effectiveness in ovarian hyperstimulation syndrome (OHSS) and their impact on endometrial receptivity in a rat model.

STUDY DESIGN: A total of 25 immature Wistar female rats were randomly assigned to 5 groups: group 1 (control), group 2 (hyperstimulated), group 3 (cabergoline), group 4 (2 mg/kg bromocriptine), and group 5 (4 mg/kg bromocriptine). Body-ovarian weights, the number of corpora lutea, and endometrial receptivity were investigated.

RESULTS: Cabergoline appeared to be less effective in reduction in body weight (p=0.042). Ovarian weight was significantly reduced by a higher dose of bromocriptine (p<0.000). The number of corpora lutea were similar. In the cabergoline group, endometrial pinopode expression was reduced. In the bromocriptine groups the presence of pinopode formation was not affected, whereas some of those displayed different structural features like dome or racket shaped of yet undetermined significance.

CONCLUSION: According to our findings, bromocriptine, particularly in higher doses, might be preferred with regard to ovarian mass suppression, weight gain, and pinopode expression. Further studies assessing the efficacy and safety of different doses of bromocriptine administration in OHSS followed by clinical trials about implantation and pregnancy rates are required.
Keywords:  bromocriptine, cabergoline, endometrial receptivity, ovarian hyperstimulation
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from